apl. Prof. Dr. Bernd Spriewald



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual (2024) Kocher K, Moosmann C, Drost F, Schülein C, Irrgang P, Steininger P, Zhong J, et al. Journal article Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia (2024) Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, et al. Journal article, Letter Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL (2024) Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, et al. Journal article Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller (2023) El Kenz B, Schmidt K, Ogungbemi-Alt VK, Bergmann S, Steininger P, Korn K, Spriewald B, et al. Journal article Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. (2023) Bergmann C, Müller F, Distler J, Györfi AH, Völkl S, Aigner M, Kretschmann S, et al. Journal article, Letter Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study (2023) Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, et al. Journal article Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution Primary cutaneous manifestation of systemically aggressive diffuse large B-cell lymphoma (2022) Bender-Säbelkampf S, Spriewald B, Berking C, Erdmann M, Wagner N Conference contribution Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients (2022) Arnold M, Heinemann FM, Oesterreich S, Wilde B, Gackler A, Goldblatt D, Spriewald B, et al. Journal article